with the endosomal membrane, allowing the virus to release its genome into the cytoplasm. Treatment The main reason that there are not many available treatments is that Ebola is such a severe virus, with a 90% fatality rate. It can only be explored in a BSL-4 laboratory which is very selective. In order for it to be studied more widely, BSL-2 laboratories have been able to use systems that are substitutes for the actual infectious virus. Scientists have used pseudo types that have the same glycoprotein on the surface that is used for entry into the host cell. They also use noninfectious Ebola-like particles as a replacement system to study. The search for a vaccine for Ebola began immediately after it was first discovered in 1976. There are currently only two FDA approved drugs. In October 2020 Immazab was officially approved and in December 2020, Ebanga was also officially approved. The difference between the two treatments is that Immazeb uses three monoclonal antibodies whereas Ebanga only has one monoclonal antibody. Both of these treatments are designed to attack the glycoprotein in order to prevent the virus from entering a new host cell and replicating. Besides these two drugs, there is more general treatment care such as managing symptoms that are caused by Ebola such as vomiting, fever, diarrhea, and any pain. Taxonomy notes According to the rules for taxon naming established by the International Committee on Taxonomy of Viruses (ICTV), the name of the genus Ebolavirus is always to be capitalized, italicized, never abbreviated, and to be preceded by the word "genus". The names of its members (ebolaviruses) are to be written in lower case, are not italicized, and used without articles. Genus inclusion criteria A virus of the family Filoviridae is a member of the genus Ebolavirus if its genome has several gene overlaps its fourth gene (GP) encodes four proteins (sGP, ssGP, Δ-peptide, and GP1,2) using cotranscriptional editing to express ssGP and GP1,2 and proteolytic cleavage to express sGP and Δ-peptide peak infectivity of its virions is associated with particles ≈805 nm in length its genome differs from that of Marburg virus by ≥50% and from that of Zaire ebolavirus by <50% at the nucleotide level its virions show almost no antigenic cross reactivity with marburg virions Classification The genera Ebolavirus and Marburgvirus were originally classified as the species of the now-obsolete genus Filovirus. In March 1998, the